121 related articles for article (PubMed ID: 35147860)
1. Pharmacokinetic studies, molecular docking, and molecular dynamics simulations of phytochemicals from Morus alba: a multi receptor approach for potential therapeutic agents in colorectal cancer.
Stany B; Mishra S; Rao KVB
Med Oncol; 2024 May; 41(6):156. PubMed ID: 38750377
[TBL] [Abstract][Full Text] [Related]
2. Computational screening of natural MtbDXR inhibitors for novel anti-tuberculosis compound discovery.
Islam S; Salekeen R; Ashraf A
J Biomol Struct Dyn; 2024 Apr; 42(7):3593-3603. PubMed ID: 37272886
[TBL] [Abstract][Full Text] [Related]
3. Kaempferol, a Phytoprogestin, Induces a Subset of Progesterone-Regulated Genes in the Uterus.
Bergsten TM; Li K; Lantvit DD; Murphy BT; Burdette JE
Nutrients; 2023 Mar; 15(6):. PubMed ID: 36986136
[TBL] [Abstract][Full Text] [Related]
4. High-throughput computational screening and
Shahrani MA; Gahtani R; Abohassan M; Alshahrani M; Alraey Y; Dera A; Asiri MR; Rajagopalan P
Oncol Res; 2023; 32(2):251-259. PubMed ID: 38186572
[TBL] [Abstract][Full Text] [Related]
5. Novel computational and drug design strategies for inhibition of human papillomavirus-associated cervical cancer and DNA polymerase theta receptor by Apigenin derivatives.
Akash S; Bayıl I; Hossain MS; Islam MR; Hosen ME; Mekonnen AB; Nafidi HA; Bin Jardan YA; Bourhia M; Bin Emran T
Sci Rep; 2023 Oct; 13(1):16565. PubMed ID: 37783745
[TBL] [Abstract][Full Text] [Related]
6. Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype.
Lupo B; Sassi F; Pinnelli M; Galimi F; Zanella ER; Vurchio V; Migliardi G; Gagliardi PA; Puliafito A; Manganaro D; Luraghi P; Kragh M; Pedersen MW; Horak ID; Boccaccio C; Medico E; Primo L; Nichol D; Spiteri I; Heide T; Vatsiou A; Graham TA; Élez E; Argiles G; Nuciforo P; Sottoriva A; Dienstmann R; Pasini D; Grassi E; Isella C; Bertotti A; Trusolino L
Sci Transl Med; 2020 Aug; 12(555):. PubMed ID: 32759276
[TBL] [Abstract][Full Text] [Related]
7. Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling.
Albadari N; Xie Y; Li W
Front Pharmacol; 2023; 14():1340401. PubMed ID: 38269272
[TBL] [Abstract][Full Text] [Related]
8. Computational insights into overcoming resistance mechanisms in targeted therapies for advanced breast cancer: focus on EGFR and HER2 co-inhibition.
Abdulaziz O; Khan FR; Alharthi NS; Alhuthali HM; Hazazi A; Alzahrani HA; Gharib AF; Alsalmi OA; Hawsawi NM; Alhazmi AY
J Biomol Struct Dyn; 2024 Jan; ():1-12. PubMed ID: 38234016
[TBL] [Abstract][Full Text] [Related]
9. In Silico Screening of Available Drugs Targeting Non-Small Cell Lung Cancer Targets: A Drug Repurposing Approach.
Thirunavukkarasu MK; Suriya U; Rungrotmongkol T; Karuppasamy R
Pharmaceutics; 2021 Dec; 14(1):. PubMed ID: 35056955
[TBL] [Abstract][Full Text] [Related]
10. Colorectal cancer drug target prediction using ontology-based inference and network analysis.
Tao C; Sun J; Zheng WJ; Chen J; Xu H
Database (Oxford); 2015; 2015():. PubMed ID: 25818893
[TBL] [Abstract][Full Text] [Related]
11. Identification of Potential Phytochemical Inhibitors From Conium maculatum Targeting the Epidermal Growth Factor Receptor in Metastatic Colorectal Cancer via Molecular Docking Analysis.
Venkateswaran S; Manivannan HP; Francis AP; Veeraraghavan VP; R G; Sankaran K
Cureus; 2023 Oct; 15(10):e48000. PubMed ID: 38034159
[TBL] [Abstract][Full Text] [Related]
12. Toxicity prediction and analysis of flavonoid apigenin as a histone deacetylase inhibitor: an in-silico approach.
Divya Rajaselvi N; Jida MD; Nair DB; Sujith S; Beegum N; Nisha AR
In Silico Pharmacol; 2023; 11(1):34. PubMed ID: 37941890
[TBL] [Abstract][Full Text] [Related]
13. Application of Pharmacokinetic Prediction Platforms in the Design of Optimized Anti-Cancer Drugs.
Beck TC; Springs K; Morningstar JE; Mills C; Stoddard A; Guo L; Moore K; Gensemer C; Biggs R; Petrucci T; Kwon J; Stayer K; Koren N; Dunne J; Fulmer D; Vohra A; Mai L; Dooley S; Weninger J; Peterson Y; Woster P; Dix TA; Norris RA
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744803
[TBL] [Abstract][Full Text] [Related]
14. Kinase-targeted therapy in subsets of colorectal cancer.
Gomez Barila PM; Medema JP
Oncoscience; 2023; 10():24-26. PubMed ID: 37383222
[No Abstract] [Full Text] [Related]
15. Integrated blood and organ profile analysis to evaluate ameliorative effects of kaempferol on 5-fluorouracil-induced toxicity.
Sharma A; Chorawala MR; Rawal RM; Shrivastava N
Sci Rep; 2024 Jan; 14(1):2363. PubMed ID: 38287048
[TBL] [Abstract][Full Text] [Related]
16. Unraveling the therapeutic potential of
Balkrishna A; Sharma D; Thapliyal M; Arya V; Dabas A
In Silico Pharmacol; 2024; 12(1):3. PubMed ID: 38108042
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Galangin and Its In Vitro/In Vivo Metabolites via Ultra-High-Performance Liquid Chromatography/Quadrupole Time-of-Flight Mass Spectrometry.
Zhao F; Ma Y; Yin J; Li Y; Cao Y; Zhang L
Metabolites; 2022 Oct; 12(11):. PubMed ID: 36355115
[TBL] [Abstract][Full Text] [Related]
18. Reckoning apigenin and kaempferol as a potential multi-targeted inhibitor of EGFR/HER2-MEK pathway of metastatic colorectal cancer identified using rigorous computational workflow.
Sharma A; Sinha S; Rathaur P; Vora J; Jha PC; Johar K; Rawal RM; Shrivastava N
Mol Divers; 2022 Dec; 26(6):3337-3356. PubMed ID: 35147860
[TBL] [Abstract][Full Text] [Related]
19. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
